In late April, Novartis announced plans to add a new facility in Morrisville, North Carolina, focused on active pharmaceutical ingredient (API) manufacturing for solid dosage tablets, capsules and RNA therapeutics. The facility represents a critical step that will strengthen end‑to‑end U.S. production capability from active ingredients through finished medicines.
This is company’s seventh new facility planned within a year of its announced $23 billion investment in U.S.-based manufacturing, research and development. The 56,200-square-foot facility will expand the company’s presence in North Carolina to five facilities across three sites. The infrastructure will support not only current medicines, but also the development and delivery of future innovative therapies for U.S. patients.
“Last year we committed to adding seven new facilities in the U.S., and today we finalize our plans to expand our U.S. manufacturing and R&D footprint in the US,” said Vas Narasimhan, CEO of Novartis. “By building a connected, end-to-end footprint, we are strengthening our ability to locally develop, produce, and deliver medicines at scale, enabling timely access to innovation for patients in the US.”
The company plans to invest an additional $220M in a new building at Pathway Triangle. This is in addition to the company’s announcement last November that committed $231 million and over 100 jobs in Morrisville. The company expects to create more than 700 new jobs in Durham and Wake Counties by the end of 2030.
“Novartis’s expanded investment reinforces what companies continue to see in Wake County: a deep life sciences ecosystem, a strong talent pipeline and partners committed to helping projects move from concept to reality,” said Michael Haley, Executive Director of Wake County Economic Development. “This manufacturing facility adds strategic capacity to the region and will create high-quality jobs that strengthen our economy for years to come.”
Novartis Breaks Ground In Texas
Last week, Novartis broke ground on its new 46,000-square-foot radioligand therapy (RLT) manufacturing site in Denton, Texas, the latest milestone in its broader $23 billion investment in U.S. manufacturing and research. The start of construction on the company’s first Texas‑based manufacturing facility brings US RLT production closer to patients across the southern U.S,. becoming the fifth RLT site nationwide.
A lead-shielded canister that contains radioligand therapy doses. (Photo: Novartis)
“Radioligand therapy is transforming how we treat cancer, and expanded manufacturing is essential to delivering these therapies at scale,” said Narasimhan. “Breaking ground in Denton further strengthens our U.S. supply chain and helps ensure patients can receive these highly personalized treatments when and where they need them.”
This expansion reinforces Novartis’ leadership as the first company to deliver RLT at scale, building the network capacity needed as these therapies extend into earlier stages of treatment and a broader range of cancers. Announced earlier this year, the site is expected to become operational in 2028 and create new U.S.-based Novartis jobs in bioengineering, advanced manufacturing, quality, and operations, supporting economic growth in Denton and surrounding communities.
“I’m pleased to welcome Novartis to Denton as their newest manufacturing location for their cancer therapies,” said Texas State Senator Brent Hagenbuch at the groundbreaking event. “Their decision establishes a strong partnership and reflects the unique opportunity Denton provides to a well-educated workforce, and the unique access the new plant location will provide to the vibrant North Texas economy and rapidly growing state population.”
The Texas facility bolsters the Novartis coast-to-coast RLT manufacturing network, with existing U.S. sites in New Jersey, Indiana and California, and a new site being added in Florida. The Denton site adds to the largest U.S. RLT manufacturing network and further builds on the company’s longstanding track record of enabling >99% of doses to be administered on the planned day of treatment. Each dose of RLT is custom-made and requires precise coordination, making manufacturing reliability and proximity to treatment centers critical to delivering treatment as planned.
Novartis’ U.S. Investment Timeline
In April 2025, Novartis committed $23 billion over five years to grow its US research and manufacturing footprint. Seven new and three expanded facilities across the country are already under construction – part of the company’s broader effort to manufacture all key medicines for US patients in the US, supporting supply resilience and dependable delivery of medicines. The Denton groundbreaking builds on rapid progress across Novartis’ US investment plan.
May 2026: Breaking ground on a new RLT manufacturing facility in Denton, Texas, to produce cancer treatments, expanding the company’s coast-to-coast RLT network to five sites (site location previously announced in February 2026)April 2026: Announced a new facility in Morrisville, North Carolina, focused on active pharmaceutical ingredient manufacturing for solid dosage tablets, capsules and RNA therapeutics across oncology, immunology, and cardiovascular, renal and metabolic diseasesFebruary 2026: Broke ground on a new biomedical research center in San Diego, California, expanding its US research presence alongside Cambridge, Massachusetts, and supporting discovery across disease areas including neuroscience and oncologyJanuary 2026: Announced a new RLT manufacturing facility for cancer treatments in Winter Park, Florida, the first in the southeastern USDecember 2025: Broke ground on a flagship manufacturing hub in North Carolina, adding solid dosage tablet and capsule and biologics production and sterile packaging for treatments across oncology, immunology, neuroscience, and cardiovascular, renal and metabolic diseasesNovember 2025: Opened a new RLT manufacturing facility for cancer treatments in Carlsbad, California – the first such site in the region serving the western US, Alaska, and HawaiiOngoing: Expansions of existing RLT facilities in Indianapolis, Indiana, and Millburn, New Jersey, supporting current and future demand for these cancer treatments
The company is on track to establish end-to‑end manufacturing for all advanced technology platforms in the U.S., including small and large molecules, and radioligand, RNA therapeutics, cell and gene therapies — a first in Novartis history.